Global Influenza Vaccine Market Assessment, By Vaccine Type [Inactivated Influenza Vaccine, Live Attenuated Influenza Vaccine], By Type of Influenza [Seasonal and Pandemic], By Formulation [Trivalent, Quadrivalent], By Technology [Egg-based, Cell culture and Recombinant], By Age group [Paediatric and Adult], By Route of Administration [Intra-Muscular Injection, Nasal Spray], By Distribution Channel [Hospital, Retail Pharmacies, Government Suppliers and Others], By Region, By Opportunities and Forecast, 2016-2030F
Global Influenza Vaccine Market size was valued at USD 8.02 billion in 2022 which is expected to reach USD 11.78 billion in 2030 growing with a CAGR of 4.92% for the forecast period between 2023 and 2030.
Home>Industry Reports>Global Influenza Vaccine Market Assessment, Opportunities and Forecast, 2016-2030F
Global Influenza Vaccine Market size was valued at USD 8.02 billion in 2022 which is expected to reach USD 11.78 billion in 2030 growing with a CAGR of 4.92% for the forecast period between 2023 and 2030. The drivers fuelling the growth of the worldwide influenza vaccine market include the high prevalence of influenza, increased government attention on immunization programmes, newly developed vaccines, and technological advancements in vaccine administration. The influenza epidemics are responsible for 2,90,000 to 6,50,000 respiratory deaths and 3 to 5 million cases of severe illness globally each year. The annual global attack rate for influenza is estimated to be 5–10% in adults and 20–30% in children. The elderly, expectant mothers, small children, and those with underlying medical issues are the groups that are highly susceptible to flu.
Twice a year, new flu vaccines are manufactured for the winter season in each hemisphere. This frequency is necessary due to the rapid mutation of the virus and changes in circulation patterns between consecutive winter seasons, which causes the effectiveness of previous vaccinations to diminish. Owing to the mutated new strains of influenza in circulation, particularly in northern and southern hemispheres, numerous seasonal influenza vaccines are reformulated each year. Hence, despite the immunity developed in patients due to older generation of vaccines, patients are required to vaccinated with reformulated versions each year to enhance immune response, thereby contributing to the demand for new reformulated vaccines and market growth.
The best method of preventing illness and serious consequences brought on by influenza viruses is vaccination. To create a unified strategy for the development of influenza vaccines, including their efficient use and distribution, production, testing, and regulatory control, World Health Organization (WHO) has been working with scientists and policymakers on a worldwide scale for more than 50 years.
Increasing Demand from Developing Countries
According to WHO, developing nations account for 99% of lower respiratory tract infection-related mortality in children under the age of five. Seasonal influenza can have a significant direct or indirect negative impact on both health and the economy. It can cause high rates of absence from work, productivity loss, and a heavy demand on healthcare systems, which can affect hospital capacity and medical expenditures. Many low and middle-income countries (LICs and MICs) lack accurate statistics on the disease burden caused by seasonal influenza, even though research indicates that these nations are likely to have the largest burden of influenza among children and other populations at risk.
For instance, after receiving market authorization for the trivalent seasonal influenza vaccine developed by the Serbian Institute of Virology, Vaccines and Sera- Torlak in August 2020, Serbia's efforts to establish and maintain domestic vaccine production has helped in ensuring the nation has a reliable and independent supply of influenza vaccines.
Development of New Vaccines Driving the Market
Although the strains of the currently available vaccines closely match the strains of the influenza virus in circulation, these vaccines usually provide only 40%-60% protection, with considerably lower protection in years due to insufficient strain matching. Since the strains chosen for the vaccine are selected six months prior to the inception of the influenza season that they are meant to combat, it is challenging for global health experts to determine which strains would be the best match for the upcoming season. Better strain matching may be possible in the future owing to mRNA technology's adaptability and faster production. Further, in event of a pandemic, influenza or outbreak, mRNA technology can help in faster mass production of vaccinations as mRNA-based influenza vaccines need the virus' genetic makeup.
For instance, Pfizer, one of the world’s premier biopharmaceutical companies, initiated phase 3 study of single dose m-RNA based influenza vaccine in September 2022. With only the genetic makeup of the viruses required, mRNA-based vaccinations can be produced more quickly and with greater flexibility, potentially improving strain matching and the efficacy of current flu vaccines.
Government Initiatives
Governments around the globe are taking several initiatives to ensure the widespread availability and administration of influenza vaccines. These efforts are aimed at protecting public health and minimizing the impact of seasonal flu outbreaks. Some of the notable initiatives being taken by governments are vaccine production and distribution, surveillance and monitoring, vaccination programs, R&D and public awareness campaigns.
For instance, on 24th April 2023, Australian Government’s Department of Health and Aged Care, launched an 8-week public awareness campaign under the National Immunization Program (NIP) to help and educate the people about the serious consequences of influenza. It is crucial for those who are more likely to experience difficulties from the flu, such as pregnant women and their unborn children, kids between the ages of 6 months to 5 years, and members of first nations communities.
Recombinant Vaccines Offers Clinical Advantage for Geriatric Patients
The recombinant flu vaccine is among the top three vaccines recommended specifically for individuals aged 65 and above. This preference is due to the reason that these vaccines demonstrate higher efficacy compared to standard dose unadjuvanted flu vaccines in this age group. In the event of a pandemic or during scarcity of the eggs required to develop influenza viruses, the production procedure for recombinant vaccines is quicker than that for vaccines based on eggs because it is not dependent on an egg supply. The choice of vaccine viruses that are adapted for growth in eggs does not impose any restrictions on recombinant method.
For instance, Flublok Quadrivalent, developed by Sanofi Pasteur Inc., a recombinant flu shot is available for the 2022-2023 influenza season. It is recommended for active immunization against illness brought on by the type B and influenza A subtype viruses and can be used by those who are at least 18 years old.
Increasing Adoption of Inactivated Influenza Vaccines
Inactivated influenza vaccine is crucial in managing the spread of flu virus. These vaccines are made from dead strains of flu virus and are considered highly effective. One of the most important benefits of this vaccine is the safety of the recipient’s health. Since the virus strains used in the creation of this vaccine are dead, hence it is incapable of causing a flu infection.
This makes inactivated vaccines suitable for people at a higher risk of serious complications, such as pregnant women, people with compromised immune system and children. Each year, a trivalent influenza vaccine is developed based on the influenza viruses expected to be common during the upcoming flu season. This medication can be prepared for injection or intranasal use.
For instance, Fluarix (2022-2023 formula), developed by GSK, is a trivalent inactivated influenza vaccine. It is a synthetic vaccine consisting of three inactivated influenza viruses, two different influenza type A strains and one influenza type B strain.
Impact of COVID-19
As per UNICEF (United Nations International Children’s Emergency Fund), the global demand for influenza vaccine has increased due to the COVID-19 pandemic. To ensure that countries receive the influenza vaccines in a timely manner and in sufficient quantities, a supply document has been issued. This document addresses crucial concerns related to the vaccine production process, procurement and supply information. The delivery of medical services around the world was hampered by the COVID-19 pandemic. Due to the 2019–2020 seasonal flu in the Northern Hemisphere and COVID–19 in the Southern Hemisphere, there has been an increase in the occurrence of coinfections, which has resulted in worse outcomes and excess mortality. Influenza vaccination reduced the occurrence of COVID-19 cases, hospitalizations, admissions to critical care units, and COVID-19-related mortality. By reducing the burden of influenza disease and enhancing the distinction between influenza and COVID-19—two diseases with similar signs and symptoms—influenza vaccination can thereby reduce the demand on healthcare resources brought on by the COVID-19 pandemic.
Global Influenza Vaccine Market: Report Scope
“Global Influenza Vaccine Market Assessment, Opportunities, and Forecast, 2016-2030F”, is a comprehensive report by Markets & Data, providing in-depth analysis and assessment of the current scenario of the Global Influenza Vaccine Market, industry dynamics and challenges. The report includes market size, segmental shares, growth trends, COVID-19 impact, opportunities, and forecasts (2023-2030). Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.
|
Report Attribute |
Details |
|
Base Year of the Analysis |
2022 |
|
Historical Period |
2016-2021 |
|
Forecast Period |
2023-2030 |
|
Projected Growth Rate |
CAGR of 4.92% between 2023-2030 |
|
Revenue Forecast in 2030 |
USD 11.78 billion |
|
Units |
Revenue in USD billion |
|
Segments Covered |
Type of Vaccine, Type of Influenza, Formulation, Technology, Age group, Route of administration, Distribution channel |
|
Regions Covered |
North America, South America, Europe, Asia-Pacific, Middle East and Africa |
|
Key Companies Profiled |
Sanofi Pasteur Inc., GlaxoSmithKline PLC., AstraZeneca PLC., Abbott Healthcare Pvt Ltd., F. Hoffmann-La Roche Ltd., Biken Co. Ltd., Novartis AG, Gamma Vaccines Pty Ltd., CSL Limited., BioDiem Ltd., Sinovac Biotech Ltd., Viatris Inc. |
|
Customization Scope |
15% free report customization with purchase |
|
Pricing and Purchase Options |
Avail the customized purchase options to fulfil your precise research needs |
|
Delivery Format |
PDF and Excel through email (subject to the license purchased) |
In this report, Global Influenza Vaccine Market has been segmented into the following categories:
1. By Type of Vaccine
1.1 Inactivated Influenza Vaccine
1.2 Live Attenuated Influenza Vaccine
2. By Type of Influenza
2.1. Seasonal
2.2. Pandemic
3. By Formulation
3.1. Trivalent
3.1.1.Standard Dose Unadjuvanted
3.1.2.High Dose Unadjuvanted
3.1.3.Adjuvanted
3.2. Quadrivalent
3.2.1.Standard Dose Unadjuvanted
3.2.2.Unadjuvanted
4. By Technology
4.1. Egg-based
4.2. Cell culture
4.3. Recombinant
5. By Age Group
5.1. Paediatric
5.2. Adult
6. By Route of Administration
6.1. Intra-muscular injection
6.2. Nasal Spray
7. By Distribution Channel
7.1. Hospital
7.2. Retail Pharmacies
7.3. Government Suppliers
7.4. Others
8. By Region
8.1. North America
8.2. Europe
8.3. Asia-Pacific
8.4. South America
8.5. Middle East and Africa
Key Players Landscape and Outlook
Pharmaceutical companies are engaging in mergers and acquisitions, joint ventures, and extensive collaborations for the manufacturing of influenza vaccines. The dominant market players are aiming to combine their coronavirus vaccines with annual flu shots. Furthermore, executives representing various vaccine manufacturers have expressed their expectations of a gradual transformation of the COVID-19 vaccine market to resemble the industry dynamics observed in the flu vaccine sector.
In November 2022, Pfizer Inc. and BioNTech SE announced the advancement of an mRNA-based combination vaccine candidate for influenza and COVID-19 to a Phase 1 trial with the aim to treat two serious respiratory diseases with a single vaccination.
Market Xcel’s reports answer the following questions:
• What is the current and future market size of the product/service in question globally or specific to different countries?
• How are the markets divided into different product/service segments and the market size and growth of each segment?
• What is the market potential of different product segments and their investment case?
• How are the markets predicted to develop in the future and what factors will drive or inhibit growth?
• What is the business environment and regulatory landscape specific to the product/service?
Key Players Operating in Global Influenza Vaccine Market
· Sanofi Pasteur Inc.
· GlaxoSmithKline PLC.
· AstraZeneca PLC.
· Abbott Healthcare Pvt Ltd.
· F. Hoffmann-La Roche Ltd.
· Biken Co., Ltd.
· Gamma Vaccines Pty Ltd.
· CSL Limited.
· BioDiem Ltd.
· Sinovac Biotech Ltd
· Viatris Inc.
If you can't find what you're searching for or have any custom requirements for Global Influenza Vaccine Market, you may approach our team at info@marketsandata.com
Table of Contents
1. Research Methodology
2. Project Scope & Definitions
3. Impact of Covid-19 on Global Influenza Vaccine Market
4. Executive Summary
5. Global Influenza Vaccine Market Outlook, 2016-2030F
5.1. Market Size & Forecast
5.1.1.By Value
5.1.2.By Volume
5.1. By Type of Vaccine
5.1.1. Inactivated Influenza Vaccine
5.1.2. Live Attenuated Influenza Vaccine
5.2. By Type of Influenza
5.2.1. Seasonal
5.2.2. Pandemic
5.3. By Formulation
5.3.1. Trivalent
5.3.1.1. Standard Dose Unadjuvanted
5.3.1.2. High Dose Unadjuvanted
5.3.1.3. Adjuvanted
5.3.2. Quadrivalent
5.3.2.1. Standard Dose Unadjuvanted
5.3.2.2. Unadjuvanted
5.4. By Technology
5.4.1. Egg-based
5.4.2. Cell culture
5.4.3. Recombinant
5.5. By Age Group
5.5.1. Paediatric
5.5.2. Adult
5.6. By Route of Administration
5.6.1. Intra-muscular injection
5.6.2. Nasal Spray
5.7. By Distribution Channel
5.7.1. Hospital
5.7.2. Retail Pharmacies
5.7.3. Government Suppliers
5.7.4. Others
5.8. By Region
5.8.1. North America
5.8.2. Europe
5.8.3. South America
5.8.4. Asia-Pacific
5.8.5. Middle East and Africa
5.9. By Company Market Share (%), 2022
6. Global Influenza Vaccine Market Outlook, By Region, 2016-2030F
6.1. North America*
6.1.1. By Category
6.1.1.1. Inactivated Influenza Vaccine
6.1.1.2. Live Attenuated Influenza Vaccine
6.1.2. By Type of Influenza
6.1.2.1. Seasonal
6.1.2.2. Pandemic
6.1.3. By Formulation
6.1.3.1. Trivalent
6.1.3.1.1. Standard Dose Unadjuvanted
6.1.3.1.2. High Dose Unadjuvanted
6.1.3.1.3. Adjuvanted
6.1.3.2. Quadrivalent
6.1.3.2.1. Standard Dose Unadjuvanted
6.1.3.2.2. Unadjuvanted
6.1.4. By Technology
6.1.4.1. Egg-based
6.1.4.2. Cell culture
6.1.4.3. Recombinant
6.1.5. By Age Group
6.1.5.1. Paediatric
6.1.5.2. Adult
6.1.6. By Route of Administration
6.1.6.1. Intra-muscular injection
6.1.6.2. Nasal Spray
6.1.7. By Distribution Channel
6.1.7.1. Hospital
6.1.7.2. Retail Pharmacies
6.1.7.3. Government Suppliers
6.1.7.4. Others
6.1.8. United States*
6.1.8.1. By Category
6.1.8.1.1. Inactivated Influenza Vaccine
6.1.8.1.2. Live Attenuated Influenza Vaccine
6.1.8.1.3. Adjuvanted
6.1.8.2. By Type of Influenza
6.1.8.2.1. Seasonal
6.1.8.2.2. Pandemic
6.1.8.3. By Formulation
6.1.8.3.1. Trivalent
6.1.8.3.1.1. Standard Dose Adjuvanted
6.1.8.3.1.2. High Dose Unadjuvanted
6.1.8.3.1.3. Adjuvanted
6.1.8.3.2. Quadrivalent
6.1.8.3.2.1. Standard Dose Unadjuvanted
6.1.8.3.2.2. Unadjuvanted
6.1.8.4. By Technology
6.1.8.4.1. Egg-based
6.1.8.4.2. Cell culture
6.1.8.4.3. Recombinant
6.1.8.5. By Age Group
6.1.8.5.1. Paediatric
6.1.8.5.2. Adult
6.1.8.6. By Route of Administration
6.1.8.6.1. Intra-muscular injection
6.1.8.6.2. Nasal spray
6.1.8.7. By Distribution Channel
6.1.8.7.1. Hospital
6.1.8.7.2. Retail Pharmacies
6.1.8.7.3. Government Suppliers
6.1.8.7.4. Others
6.1.9. Canada
6.1.10. Mexico
*All segments will be provided for all regions and countries covered
6.2. Europe
6.2.1 Germany
6.2.2 France
6.2.3 Italy
6.2.4 United Kingdom
6.2.5 Russia
6.2.6 Netherlands
6.2.7 Spain
6.2.8 Turkey
6.2.9 Poland
6.3. South America
6.3.1. Brazil
6.3.2. Argentina
6.4. Asia-Pacific
6.4.1. India
6.4.2. China
6.4.3. Japan
6.4.4. Australia
6.4.5. Vietnam
6.4.6. South Korea
6.4.7. Indonesia
6.4.8. Philippines
6.5. Middle East & Africa
6.5.1. Saudi Arabia
6.5.2. UAE
6.5.3. South Africa
7. Market Mapping, 2022
7.1. By Type of Vaccine
7.2. By Type of Influenza
7.3. By Formulation
7.4. By Technology
7.5. By Age Group
7.6. By Route of Administration
7.7. By Distribution Channel
8. Macro Environment and Industry Structure
8.1. Supply Demand Analysis
8.2. Import Export Analysis
8.3. Value Chain Analysis
8.4. PESTEL Analysis
8.4.1. Political Factors
8.4.2. Economic System
8.4.3. Social Implications
8.4.4. Technological Advancements
8.4.5. Environmental Impacts
8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
8.5. Porter’s Five Forces Analysis
8.5.1. Supplier Power
8.5.2. Buyer Power
8.5.3. Substitution Threat
8.5.4. Threat from New Entrant
8.5.5. Competitive Rivalry
9. Market Dynamics
9.1. Growth Drivers
9.2. Growth Inhibitors (Challenges and Restraints)
10. Regulatory Framework and Innovation
10.1 Clinical Trials
10.2 Patent Landscape
10.3 Regulatory Approvals
10.4 Innovations/Emerging Technologies
11. Key Players Landscape
11.1. Competition Matrix of Top Five Market Leaders
11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
11.4. SWOT Analysis (For Five Market Players)
11.5. Patent Analysis (If Applicable)
12. Pricing Analysis
13. Case Studies
14. Key Players Outlook
14.1. Sanofi Pasteur Inc.
14.1.1. Company Details
14.1.2. Key Management Personnel
14.1.3. Products & Services
14.1.4. Financials (As reported)
14.1.5. Key Market Focus & Geographical Presence
14.1.6. Recent Developments
14.2. GlaxoSmithKline PLC.
14.3. AstraZeneca PLC.
14.4. Abbott Healthcare Pvt Ltd.
14.5. F. Hoffmann-La Roche Ltd.
14.6. Biken Co., Ltd.
14.7. Gamma Vaccines Pty Ltd.
14.8. CSL Limited.
14.9. Biodeme Ltd.
14.10. Sinovac Biotech Ltd.
14.11. Viatris Inc.
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work
15. Strategic Recommendations
16. About Us & Disclaimer
List of Figure_Global Influenza Vaccine Market
Figure 1. Global Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 2. Global Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 3. Global Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 4. Global Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 5. Global Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 6. Global Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 7. Global Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 8. Global Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 9. Global Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 10. Global Influenza Vaccine Market Share, By Region, In USD Billion, 2016-2030F
Figure 11. North America Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 12. North America Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 13. North America Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 14. North America Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 15. North America Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 16. North America Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 17. North America Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 18. North America Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 19. North America Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 20. North America Influenza Vaccine Market Share, By Country, In USD Billion, 2016-2030F
Figure 21. United States Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 22. United States Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 23. United States Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 24. United States Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 25. United States Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 26. United States Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 27. United States Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 28. United States Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 29. United States Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 30. Canada Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 31. Canada Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 32. Canada Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 33. Canada Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 34. Canada Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 35. Canada Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 36. Canada Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 37. Canada Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 38. Canada Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 39. Mexico Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 40. Mexico Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 41. Mexico Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 42. Mexico Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 43. Mexico Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 44. Mexico Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 45. Mexico Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 46. Mexico Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 47. Mexico Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 48. Europe Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 49. Europe Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 50. Europe Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 51. Europe Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 52. Europe Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 53. Europe Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 54. Europe Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 55. Europe Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 56. Europe Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 57. Europe Influenza Vaccine Market Share, By Country, In USD Billion, 2016-2030F
Figure 58. Germany Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 59. Germany Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 60. Germany Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 61. Germany Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 62. Germany Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 63. Germany Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 64. Germany Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 65. Germany Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 66. Germany Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 67. France Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 68. France Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 69. France Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 70. France Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 71. France Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 72. France Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 73. France Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 74. France Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 75. France Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 76. Italy Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 77. Italy Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 78. Italy Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 79. Italy Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 80. Italy Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 81. Italy Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 82. Italy Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 83. Italy Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 84. Italy Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 85. United Kingdom Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 86. United Kingdom Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 87. United Kingdom Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 88. United Kingdom Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 89. United Kingdom Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 90. United Kingdom Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 91. United Kingdom Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 92. United Kingdom Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 93. United Kingdom Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 94. Russia Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 95. Russia Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 96. Russia Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 97. Russia Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 98. Russia Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 99. Russia Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 100. Russia Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 101. Russia Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 102. Russia Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 103. Netherlands Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 104. Netherlands Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 105. Netherlands Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 106. Netherlands Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 107. Netherlands Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 108. Netherlands Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 109. Netherlands Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 110. Netherlands Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 111. Netherlands Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 112. Spain Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 113. Spain Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 114. Spain Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 115. Spain Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 116. Spain Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 117. Spain Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 118. Spain Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 119. Spain Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 120. Spain Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 121. Turkey Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 122. Turkey Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 123. Turkey Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 124. Turkey Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 125. Turkey Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 126. Turkey Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 127. Turkey Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 128. Turkey Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 129. Turkey Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 130. Poland Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 131. Poland Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 132. Poland Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 133. Poland Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 134. Poland Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 135. Poland Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 136. Poland Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 137. Poland Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 138. Poland Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 139. South America Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 140. South America Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 141. South America Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 142. South America Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 143. South America Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 144. South America Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 145. South America Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 146. South America Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 147. South America Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 148. South America Influenza Vaccine Market Share, By Country, In USD Billion, 2016-2030F
Figure 149. Brazil Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 150. Brazil Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 151. Brazil Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 152. Brazil Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 153. Brazil Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 154. Brazil Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 155. Brazil Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 156. Brazil Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 157. Brazil Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 158. Argentina Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 159. Argentina Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 160. Argentina Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 161. Argentina Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 162. Argentina Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 163. Argentina Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 164. Argentina Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 165. Argentina Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 166. Argentina Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 167. Asia-Pacific Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 168. Asia-Pacific Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 169. Asia-Pacific Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 170. Asia-Pacific Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 171. Asia-Pacific Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 172. Asia-Pacific Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 173. Asia- Pacific Cream Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 174. Asia-Pacific Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030
Figure 175. Asia-Pacific Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 176. Asia-Pacific Influenza Vaccine Market Share, By Country, In USD Billion, 2016-2030F
Figure 177. India Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 178. India Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 179. India Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 180. India Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 181. India Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 182. India Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 183. India Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 184. India Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 185. India Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 186. China Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 187. China Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 188. China Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 189. China Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 190. China Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 191. China Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 192. China Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 193. China Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 194. China Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 195. Japan Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 196. Japan Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 197. Japan Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 198. Japan Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 199. Japan Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 200. Japan Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 201. Japan Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 202. Japan Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 203. Japan Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 204. Australia Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 205. Australia Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 206. Australia Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 207. Australia Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 208. Australia Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 209. Australia Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 210. Australia Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 211. Australia Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 212. Australia Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 213. Vietnam Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 214. Vietnam Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 215. Vietnam Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 216. Vietnam Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 217. Vietnam Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 218. Vietnam Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 219. Vietnam Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 220. Vietnam Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 221. Vietnam Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 222. South Korea Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 223. South Korea Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 224. South Korea Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 225. South Korea Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 226. South Korea Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 227. South Korea Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 228. South Korea Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 229. South Korea Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 230. South Korea Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 231. Indonesia Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 232. Indonesia Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 233. Indonesia Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 234. Indonesia Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 235. Indonesia Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 236. Indonesia Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 237. Indonesia Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 238. Indonesia Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 239. Indonesia Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 240. Philippines Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 241. Philippines Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 242. Philippines Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 243. Philippines Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 244. Philippines Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 245. Philippines Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 246. Philippines Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 247. Philippines Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 248. Philippines Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 249. Middle East & Africa Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 250. Middle East & Africa Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 251. Middle East & Africa Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 252. Middle East & Africa Influenza Vaccine Market Share, By Type of vaccine, In Units Thousand, 2016-2030F
Figure 253. Middle East & Africa Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 254. Middle East & Africa Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 255. Middle East & Africa Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 256. Middle East & Africa Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 257. Middle East & Africa Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 258. Middle East & Africa Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 259. Middle East & Africa Influenza Vaccine Market Share, By Country, In USD Billion, 2016-2030F
Figure 260. Saudi Arabia Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 261. Saudi Arabia Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 262. Saudi Arabia Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 263. Saudi Arabia Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 264. Saudi Arabia Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 265. Saudi Arabia Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 266. Saudi Arabia Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 267. Saudi Arabia Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 268. Saudi Arabia Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 269. UAE Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 270. UAE Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 271. UAE Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 272. UAE Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 273. UAE Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 274. UAE Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 275. UAE Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 276. UAE Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 277. UAE Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 278. South Africa Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
Figure 279. South Africa Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
Figure 280. South Africa Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
Figure 281. South Africa Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
Figure 282. South Africa Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
Figure 283. South Africa Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
Figure 284. South Africa Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
Figure 285. South Africa Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 286. South Africa Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 287. By Type of vaccine Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 288. By Type of Influenza Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 289. By Formulation Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 290. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 291. By Age Group Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 292. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 293. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 294. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022
List of Table_Global Influenza Vaccine Market
Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects
Frequently Asked Questions
What is the growth rate of Global Influenza Vaccine Market?
What are the major factors influencing the growth of Global Influenza Vaccine Market?
Who are the key players operating in Global Influenza Vaccine Market?
What are the regions covered in the final report for Global Influenza Vaccine Market?
See Related Reports
Global Coffee Market Assessment, Opportunities and Forecast, 2017-2031F
Global coffee market is expected to experience growth due to consumers’ increasing preference for organic and premium coffee that offers freshness, superior quality of beans and roasts, and unique flavor profile. Additionally, the product innovation,....Read More
Published on
July 2024
4,500
Global Home Theater System Market Assessment, Opportunities and Forecast, 2017-2031F
Global home theater system market is expected to experience growth due to technological advancements, increasing disposable incomes, rising demand for high-definition content, integration with smart home systems, and the surge in streaming services p....Read More
Published on
July 2024
4,500
Global Baby Food Market Assessment, Opportunities and Forecast, 2017-2031F
Global baby food market is expected to experience growth due to factors such as consumers’ increasing awareness of the nutrients which are essential for babies development and introduction of wide variety of baby foods in the market from milk powders....Read More
Published on
July 2024
4,500
Global Isoflavones Market Assessment, Opportunities and Forecast, 2017-2031F
Global isoflavones market is expected to experience growth due to increasing consumer health awareness, rising demand for functional foods and nutraceuticals, advancements in extraction technologies, and expanding applications in cosmetics, pharmaceu....Read More
Published on
July 2024
4,500
Purchase Options
USD ($)
i
3,000
i
4,500
i
5,700
i
8,200
Tired of Searching?
Looking for Customization?
Some other doubt?
Need insights from a cohort?
REACH US
